The Drug Development Process

  • Naja E. McKenzie


Chemopreventive Agent Molecular Entity Drug Developer Material Transfer Agreement Investigator Brochure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anonymous (1999). "Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research." Cancer Research 59(19): 4743–4758.PubMedGoogle Scholar
  2. FDA (1999). From test tube to patient: Improving health through human drugs. Rockville, MD, Food and Drug Administration, Center for Drug Evaluation and Research.Google Scholar
  3. ICH (1994). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, ICH Secretariat.Google Scholar
  4. Kelloff, G.J., E.T. Hawk, et al. (1996). "Strategies for identification and clinical evaluation of promising chemopreventive agents." Oncology (Huntington) 10(10): 1471–1484; discussion 1484–1488.Google Scholar
  5. Nestle, F.O., S. Alijagic, et al. (1998). "Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells." Nature Medicine 4: 328–332.CrossRefPubMedGoogle Scholar
  6. O'Shaughnessy, J.A., G.J. Kelloff, et al. (2002). "Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development [comment]." Clinical Cancer Research 8(2): 314–346.PubMedGoogle Scholar
  7. WMA (1989) World Medical Association Declaration of Helsinki, World Medical Association.Google Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • Naja E. McKenzie
    • 1
  1. 1.College of MedicineUniversity of ArizonaTucson

Personalised recommendations